# GlaxoWellcome Production – FDA Inspection, Mar 3, 2017

Source: https://www.keypedia.com/records/fda_inspections/glaxowellcome-production/b673f0a0-aaff-450b-b76a-74f9a1411f35
Source feed: FDA_Inspections

> FDA inspection 1005796 of GlaxoWellcome Production, March 03, 2017. Classification: Voluntary Action Indicated (VAI). 1 citation under 21 CFR part 314. Form 483 issued. 4 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1005796
- Company Name: GlaxoWellcome Production
- Inspection Date: 2017-03-03
- Classification: Voluntary Action Indicated (VAI)
- Classification Code: VAI
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Center: Human Drugs
- Office Name: Center for Drug Evaluation and Research
- Citation Count: 1

## Related Documents

- FDA Inspection 1242271 - 2022-04-08
- FDA Inspection 886660 - 2014-04-11
- FDA Inspection 772742 - 2012-02-27
- FDA Inspection 572931 - 2009-03-19

## Related Officers

- [Bijoy Panicker](https://www.keypedia.com/people/bijoy-panicker/1c6ec57f-e02e-49b8-8b59-1853f3d2947a)
- [Issuing Officer](https://www.keypedia.com/people/patric-c-klotzbuecher/cbb2e6b5-b001-457e-9073-33535f02926e)

Company: https://www.keypedia.com/companies/glaxowellcome-production/f88b8738-02c0-496c-bdc6-4d9f893e1cb8

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c